Microbix Forms Special Workgroup to Double Flu Vaccine Output
Microbix Biosystems Inc. (Toronto, Canada, www.microbix.com), is establishing a special workgroup for applied technology transfer (SWATT) that will help manufacturers significantly boost the amount of flu vaccine produced throughout the world.
Microbix Biosystems Inc. (Toronto, Canada, www.microbix.com), is establishing a special workgroup for applied technology transfer (SWATT) that will help manufacturers significantly boost the amount of flu vaccine produced throughout the world. The SWATT team will be sent to facilities adopting Microbix’s proprietary virus yield enhancement technology, called Virusmax. The team is expected to be operational this fall. It will spend several weeks in each location helping customers implement the technology and training local personnel. At present, only about 350 million doses of flu vaccine are produced annually in the world, with only three countries producing enough vaccine domestically to immunize their populations.
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
